Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

The new lower prices apply to some doses of Zepbound provided in vials but not the autoinjector pens.

Investing.com -- 制药巨头礼来公司（NYSE: LLY）今日宣布推出7.5 mg和10 mg剂量的Zepbound（tirzepatide）单剂量注射液，在Zepbound自费项目下价格为$499。此外，礼来还降低了2.5 mg和5 ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound. For many consumers, their insurance denies them ...

在肥胖症愈发成为全球公共卫生问题的当下，许多制药公司开始探索更为便宜且可及的治疗方案。2024年2月15日，全球知名制药公司礼来宣布，他们的减重药物‘替尔泊肽（Zepbound）’将在美国降价，推出7.5mg和10mg的单剂量小瓶，并通过自付疗程计划每月只需499美元，这一消息引发了业内和消费者的广泛关注。这一举措不仅是药物价格透明化的重要一步，也为不少肥胖症患者带来了希望，彰显了加强患者医疗可及 ...